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Breast cancer is the most common malignancy among women and has poor survival and high recurrence
rates for aggressive metastatic disease. Notably, triple-negative breast cancer (TNBC) is a highly aggressive
cancer and there is no preferred agent for TNBC therapy. In this study, we show that a novel agent,
2-(4-hydroxy-3-methoxyphenyl)-benzothiazole (YL-109), has ability to inhibit breast cancer cell growth and
invasiveness in vitro and in vivo. In addition, YL-109 repressed the sphere-forming ability and the expression
of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl
terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of
breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the
recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells.
Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in MDA-MB-231
cells. Taken together, our findings indicate that a novel agent YL-109 inhibits cell growth and metastatic
potential by inducing CHIP expression through AhR signaling and reduces cancer stem cell properties in
MDA-MB-231 cells. It suggests that YL-109 is a potential candidate for breast cancer therapy.
B
reast cancer is the major cause of cancer death among women worldwide. Triple-negative breast cancer
(TNBC), which has been reported to represent approximately 15% of all breast cancers1, is characterized by
the absence of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth
factor-2 (HER-2) expression2. TNBC is an aggressive cancer, characterized by rapid tumor growth, a high
incidence of metastasis, an increased rate of distant recurrence, and a poor prognosis compared with other breast
cancer subtypes3. Unlike ER/PR-positive or HER-2-overexpressing subtypes, the effective treatment options for
TNBC are limited to cytotoxic therapies because of the lack of molecular targets. Moreover, TNBC cells show a
profile that is similar to breast cancer stem cells, which have a strong resistance to chemotherapeutic drugs4,5.
Therefore, new therapeutic options and strategies are required for TNBC therapy.
The carboxyl terminus of Hsp70-interacting protein (CHIP, also named STUB1) is a potential target for the
treatment of TNBC. CHIP is a U-box-type ubiquitin E3 ligase that induces ubiquitylation and degradation of its
substrates. These include several oncogenic proteins that suppress the tumorigenic and metastatic potential of
breast cancer cells6–8.We previously reported that CHIP levels weremuch higher inMCF-7 cells, a non-aggressive
cell line derived from human breast cancer cells, than in MDA-MB-231 cells, a highly aggressive cell line.
Furthermore, CHIP levels are negatively correlated with the malignancy of human breast tumor tissues9. In
addition, CHIP suppresses both tumor growth andmetastasis in a nudemouse xenograft model. Thus, it has been
suggested that the regulation of CHIP expression may represent a potential new clinical approach to TNBC
therapy.
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Aryl hydrocarbon receptor (AhR) has also recently emerged as a
potential therapeutic target for breast cancer. The AhR is a basic
helix-loop-helix transcription factor that was initially identified as
a receptor for environmental toxins, such as dioxin10. Ligand binding
to the receptor triggers formation of a heterodimeric nuclear AhR
complex, which binds to dioxin response elements in target gene
promoters to induce transcriptional activation11. Several studies have
demonstrated that the AhRmay be a potential drug target for several
diseases, including endometrial, prostate, pancreatic, and ER-pos-
itive breast cancers12–17. In addition, the antitumor effects of com-
pounds belonging to the 2-(4-amino-3-methylphenyl) benzothiazole
group are mediated by AhR in ER-positive breast cancer cells18–20.
Phortress, the lysine amide prodrug of 2-(4-amino-3-methylphenyl)-
5-fluorobenzothiazole, has completed Phase I clinical evaluations18,21.
In addition to 2-(4-aminophenyl) benzothiazoles, the relatively non-
toxic selective AhR modulators (SAhRMs) are highly effective agents
for inhibiting hormone-responsive breast cancer growth in animal
models17,22. Although 2-(4-aminophenyl) benzothiazoles and
SAhRMs are less effective against ER-negative breast cancer cells,
AhR is also expressed in these cells18,23,24. Therefore, we hypothesized
that ideal agents might exert the antitumor effects mediated by AhR
signaling in both ER-positive and -negative breast cancer cells.
In this study, we demonstrated that the novel agent 2-(4-hydroxy-
3-methoxyphenyl)-benzothiazole (YL-109) has ability to inhibit
breast cancer progression in TNBC, MDA-MB-231 cells, and ER-
positive breast cancer MCF-7 cells. In addition, YL-109 suppresses
the proliferation and invasiveness of MDA-MB-231 cells, both in
vitro and in vivo. Moreover, YL-109 suppresses the properties of
breast cancer stem cells. Furthermore, we demonstrated that YL-
109 increases CHIP expression by the recruitment of AhR to an
upstream region of the gene. Consistent with these observations,
CHIP or AhR knockdowns inhibit the suppressive effects of YL-
109 on anchorage-independent growth and invasiveness. Taken
together, our findings indicate that YL-109 is a novel antitumor agent
that can induce CHIP expression through AhR signaling, and that it
represents a promising candidate for a new therapeutic strategy
against TNBC.
Results
YL-109 inhibits cell proliferation, motility, and invasiveness in
breast cancer cells. It has been reported that 2-(4-aminophenyl)-
benzothiazoles have anti-proliferative activity inMCF-7, ER-positive
breast cancer cells18–20. Therefore, we investigated the effects of 2-(4-
hydroxy-3-methoxyphenyl)-benzothiazole, YL-109 (Figure 1a) on
cell proliferation in MCF-7 cells. YL-109 possesses characteristic
hydroxyl group at C4, whereas 2-(4-aminophenyl)-benzothiazoles
have the amino group at this position. YL-109 strongly inhibited
cell proliferation of MCF-7 cells in a dose-dependent manner (IC50
5 85.8 nM) (Figure 1b and c). Surprisingly, YL-109 had an anti-
proliferative effect in a dose-dependent manner (IC50 5 4.02 mM)
on MDA-MB-231 cells, known as TNBC cells, unlike 2-(4-
aminophenyl)-benzothiazoles (Figure 1b and c)18. We subsequently
tested whether YL-109 inhibited anchorage-independent growth in
poly-HEMA coated plates and colony formation in soft agar
(Figure 1d and e). Under short-term detached conditions using
poly-HEMA coated plate, YL-109 suppressed cell survival in MCF-
7 cells, but not in MDA-MB-231 cells (Figure 1d). In contrast, YL-
109 decreased the number of colonies in MDA-MB-231 cells under
long-term detached conditions on soft agar (Figure 1e). Moreover, to
examine the effects of YL-109 on the metastatic and invasive
potential of MDA-MB-231 cells, we performed migration and
invasion assays. In the migration assay, YL-109 reduced the ability
of cells to migrate (Figure 1f). YL-109 also significantly decreased the
number of cells that penetrated the Matrigel-coated membrane
(Figure 1g). In addition, YL-109 inhibited cell proliferation
and invasiveness of BT-20 cells, also known as TNBC cells (see
Supplementary Fig. S1 online). These results suggest that YL-109
inhibits cell proliferation and suppresses the metastatic potential of
breast cancer cells.
YL-109 inhibits both tumor growth and cancer metastasis of
breast cancer cells in vivo. Using a nude mouse xenograft model,
we investigated the effects of YL-109 in vivo. Mice treated with
vehicle showed significantly enlarged tumors, whereas mice treated
with YL-109 showed attenuated tumor growth using MCF-7 cells
(Figure 2a). Interestingly, YL-109 also suppressed tumor growth in
mice injected withMDA-MB-231 cells (Figure 2b). Next, to examine
the effect of YL-109 against metastatic activity, we performed an in
vivo lung metastasis assay using MDA-MB-231 cells. We discovered
several metastatic tumors in the lungs of mice injected with MDA-
MB-231 cells in the vehicle (Figure 2c). Compared with the vehicle
control, YL-109 significantly reduced lung metastasis (Figure 2c).
We also quantified lung metastasis using real-time RT-PCR, which
confirmed our observations (Figure 2d). These results suggest that
YL-109 suppresses tumor progression of breast cancer cells in vivo.
YL-109 suppresses breast cancer progression by inducing CHIP
expression. We previously demonstrated that CHIP suppresses
tumorigenesis and the metastatic cellular phenotypes of breast
cancer cells both in vitro and in vivo9. It has also been indicated
that CHIP expression is significantly associated with prognostic
parameters in breast cancer patients25. Therefore, we examined
whether YL-109 induced CHIP expression. We observed that YL-
109 increased bothCHIPmRNAand protein levels (Figure 3a and b).
Next, to investigate whether the antitumor effects of YL-109 were
mediated by CHIP, we performed colony formation and Matrigel
invasion assay using siRNA for CHIP (Figure 3c–e). YL-109-induced
inhibition of cell growth and invasive potential were decreased by
CHIP knockdown (Figure 3d and e). These results demonstrate that
YL-109 inhibits breast cancer progression by inducing CHIP
expression.
YL-109 activates AhR signaling to induce CHIP expression.
Previous studies indicated that 2-(4-aminophenyl)-benzothiazoles
activate AhR and increase transcription of AhR target genes, such
as Cyp1a118–20. We observed that YL-109 induced Cyp1a1 expression
in MCF-7 and MDA-MB-231 cells (Figure 4a). To explore AhR
participation in the mechanisms underlying the induction of CHIP
by YL-109, we examined whether CHIP expression levels were
affected by knocking down of AhR with siRNA (Figure 4b and c).
We observed that YL-109-induced increases in CHIP mRNA
were reduced by AhR knockdown (Figure 4c). We subsequently
examined AhR recruitment to the promoter region in CHIP gene,
which contains potential AhR response elements. Chromatin
immunoprecipitation (ChIP) assay demonstrated that the
interaction between AhR and the CHIP promoter is potentiated by
YL-109 (Figure 4d). Our data suggest that YL-109 induces CHIP
expression through recruitment of AhR to upstream of CHIP gene.
YL-109 exerts antitumor effects through AhR signaling. To
examine whether AhR signaling mediated the inhibition of cell
proliferation by YL-109, we performed MTT assay using the AhR
antagonist a-naphtoflavone (a-NF) and siRNA against AhR
(Figure 5a and b). Treatment with a-NF and knockdown of
AhR expression abolished the inhibitory effect of YL-109 on cell
proliferation of MCF-7 cells (Figure 5a and b). Moreover, YL-109-
induced inhibition of colony formation and invasive potential were
repressed by AhR knockdown (Figure 5c and d). Our data suggest
that the antitumor effects of YL-109 are mediated by AhR signaling.
YL-109 reduces the property of cancer stem cells in breast cancer
cells.Recently, we have shown that CHIP suppresses cancer stem cell
properties in breast cancer cells26. Therefore, we evaluated whether
www.nature.com/scientificreports
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YL-109 affects breast cancer stem cells. One property of cancer stem
cells is their ability to form tumor spheres, denoted mammospheres
in the case of breast cancer27. We observed that cells derived from the
MDA-MB-231 cell line formed mammospheres, whereas YL-109
markedly inhibited mammosphere formation (Figure 6a). To
confirm the effects of YL-109 on the population of cancer
stem cells in MDA-MB-231 cells, we used flow cytometry with
cancer stem cell marker ALDH. Consistent with the effects on
mammosphere formation, YL-109 decreased ALDH-positive cell
population (Figure 6b). In addition, YL-109 significantly decreased
mRNA levels of Klf-4 and Notch target gene Hes1 in MDA-MB-231
mammosphere cultures (Figure 6c). Taken together, these results
indicate that YL-109 inhibits the properties of breast cancer stem
cells.
Discussion
In the present study, we revealed that the novel agent YL-109 has
antitumor activity in TNBC cells. It was previously reported that 2-
(4-aminophenyl)-benzothiazoles have anti-proliferative activity in
ER-positive breast cancer cells, that is mediated by the AhR signaling
pathway. AhR is expressed in breast cancer cells regardless of
ER expression23,24. However, TNBC cells exhibit a poor response to
benzothiazoles and SAhRMs because they do not activate AhR -
signaling18. Consistent with previous reports on benzothiazole anti-
tumor activity, YL-109 inhibited cell proliferation through AhR
activation in ER-positive breast cancer cells. In addition, we observed
that YL-109 could activate AhR signaling in MDA-MB-231 cells,
which is necessary for YL-109 to exert antitumor effects in these cells.
These results suggest that YL-109 inhibits breast cancer progression
by AhR signaling activation in TNBC cells.
Our results also demonstrated that the YL-109-induced AhR sig-
naling activation resulted in increased CHIP expression. We prev-
iously reported that CHIP suppresses tumor progression in human
breast cancer by inhibiting oncogenic pathways9. In mice, tumor
growth and metastasis were significantly inhibited by CHIP express-
ion, whereas CHIP knockdowns in breast cancer cells resulted in
rapid tumor growth and metastatic phenotypes. In this study, we
observed that YL-109 treatment increased CHIP expression and
CHIP knockdown inhibited the suppressive effects of YL-109 on
both breast cancer cell growth and invasiveness. Moreover, YL-109
induced CHIP expression by recruiting AhR to an upstream region
of the CHIP gene. We also found that the multiple AhR-responsive
element sites exist in the promoter region ofCHIP, which contain the
core sequence 59-GCGTG-39. Taken together, these findings indicate
S
N
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Figure 1 | Identification of a compound that inhibits cell proliferation,motility and invasiveness in breast cancer cells. (a) Structure of 2-(4-hydroxy-3-
methoxyphenyl)-benzothiazole, YL-109. (b) Effects of YL-109 on cell proliferation in breast cancer cells. MCF-7 or MDA-MB-231 cells were cultured
with the indicated concentration (shown as -logM) of YL-109. After 96 h, MTT assay was performed (MCF-7; IC505 85.8 nM, MDA-MB-231; IC505
4.02 mM). (c) Effects of YL-109 on anchorage-dependent cell growth in breast cancer cells. MCF-7 or MDA-MB-231 cells were cultured in media
containing DMSO or YL-109 (1 mM) for 96 h. The cell viability wasmeasured byMTT assays. (d and e) Effects of YL-109 on anchorage-independent cell
growth in breast cancer cells. Cells were plated on poly-HEMA (d) or soft agar (e) coated plates in the absence or presence of YL-109 (1 mM). The viable
cells were counted using Countess Automated Cell Counter (Invitrogen) (d). The colonies were examined under a microscope and colonies with a
diameter of more than 100 mmwere counted (e). (f and g) Effects of YL-109 on cell motility and invasiveness in MDA-MB-231 cells. MDA-MB-231 cells
were seeded onto filters with an 8 mm pore size in uncoated (f, migration assay) or Matrigel matrix-coated (g, invasion assay) upper chambers in the
absence or presence of YL-109 (1 mM). * indicates p,0.05 and ** indicates p,0.01 and n.s. indicates p.0.05 by student’s T test vs. DMSO-treated cells.
www.nature.com/scientificreports
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that YL-109 inhibits breast cancer progression by inducing CHIP
expression through AhR signaling.
Our data demonstrated that YL-109 increased CHIP levels in
MDA-MB-231 cells.We also observed that YL-109 inhibited anchor-
age-independent cell growth in soft agar as well as xenograft tumor
growth, but not in poly-HEMA coated plates. For assays of in vitro
cell growth, cells were detached and suspended, either in poly-
HEMA coated plates for 24 h, or in soft agar for 3 weeks. In short-
term growth experiments such as the poly-HEMA assay, we did not
observe cell growth inhibition by YL-109, because YL-109-induced
inhibition of cell growth presumably requires the elevation of CHIP
levels. Consistent with this, in long-term growth experiments such as
soft agar colony formation and xenograft tumor growth, YL-109
inhibited cell growth of TNBC cells. Furthermore, this effect was
repressed by the knockdown of CHIP or AhR in TNBC cells.
In contrast, CHIP levels are considerably higher in MCF-7 cells
than in MDA-MB-231 cells, and we observed that YL-109 did not
affect CHIP expression in MCF-7 cells (data not shown). However,
YL-109 was able to inhibit the growth of MCF-7 cells in both short-
term and long-term growth experiments. These observations suggest
that CHIP does not contribute to the effects of YL-109 on cell growth
in ER-positive breast cancer cells.
Previous studies have reported that the inhibition of ER signaling
can result from cross talk with the ligand-activated AhR. AhR ligands
strongly suppress estrogen-induced responses in the rodent uterus,
mammary tumors, and human breast cancer cells28. Treatment of
ER-positive breast cancer cells with 2,3,7,8-tetrachlorodeibenzo-p-
dioxin (TCDD) induces proteasome-dependent degradation of
endogenous ERa29. In this study, we demonstrated that YL-109 inhi-
bits cell proliferation through the AhR signaling pathway in MCF-7
Figure 2 | YL-109 suppresses both tumor growth and metastasis of breast cancer cells in vivo. (a and b) Effects of YL-109 on tumor growth in a mouse
xenograft model. Mice were treated with DMSO (vehicle) or YL-109 (15 mg/kg) for every 2 days. Tumor growth curves showed tumor volume in nude
mice inoculated with MCF-7 (a) or MDA-MB-231 cells (b). Tumor growth was monitored twice each week. Bars represent mean 1 s.d. (n53–6). *
indicates p,0.05 and ** indicates p,0.01 by two-way ANOVA with Bonferroni’s post hoc test. (c and d) Effects of YL-109 on tumor metastasis in vivo.
MDA-MB-231 cells were injected into the tail veins of nude mice. Forty-two days after the injections, lungs were collected. Representative images of
sections from lungs are shown (c). Left panels show the images ofH&E staining (50x). Immunohistochemistry for human cytokeratins is shown inmiddle
(50x) and right (200x) panels. Asterisks indicate metastatic tumor growth. The lungmetastasis was quantified by real-time RT–PCR (d). Specific primers
for human HPRT were used. * indicates p,0.05 and ** indicates p,0.01 by student’s T test vs. DMSO-treated mice.
www.nature.com/scientificreports
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cells. These findings suggest that YL-109 may induce ERa degrada-
tion because of AhR activation in ER-positive breast cancer cells.
Taken together, our results show that YL-109 suppresses cell growth
throughAhR signaling in both ER-positive and triple-negative breast
cancer cells. In TNBC cells, YL-109 increases CHIP levels by AhR
activation. In contrast, in ER-positive cells, YL-109 induces ERa
degradation by AhR activation.
The treatment options for patients with TNBC, including those
with ER-negative breast cancer, have not yet been established. In this
study, we have demonstrated that YL-109 has antitumor activity in
TNBC cells, and thus represents a potential TNBC therapy. In addi-
tion, resistance to anti-estrogens like tamoxifen is a major clinical
problem in the treatment of hormone-dependent breast cancer
including ER-positive breast cancer. Our results indicated that YL-
109 inhibited tumor growth using a different mechanism from
anti-estrogens in ER-positive breast cancer cells. Therefore, we pre-
dict that YL-109 will also exert an antitumor effect in tamoxifen-
resistant breast cancer. Thus, YL-109 might have the ability to treat
with several subtypes of breast cancer.
Drug resistance is a serious problem in breast cancer therapy,
and cancer stem cells contributed to chemotherapeutic drug and
radiation resistance30. Breast cancer stem cells form mammo-
spheres and express stem cell markers. We observed that YL-
109 markedly inhibited mammosphere formation and decreased
the ALDH-positive cell population in MDA-MB-231 cells. More-
over, YL-109 significantly decreased Klf-4 and Hes1 expression in
mammospheres derived from MDA-MB-231 cells. KLF-4 is essen-
tial for the maintenance of breast cancer stem cells and cell inva-
siveness31, and Hes1 is a target of Notch signaling, which may be
important for the self-renewal of breast cancer stem cells32,33.
β β
Figure 3 | YL-109 inhibits breast cancer progression by inducing CHIP expression. (a and b) Effect of YL-109 on CHIP levels in MDA-MB-231 cells.
MDA-MB-231 cells were cultured in the absence or presence of YL-109 (1 mM). Total RNA was prepared from the indicated cells and the expression of
CHIP was analyzed using real-time RT–PCR (a). Protein levels of CHIP were determined by Western blotting (b). Full length images of blots are
represented in Supplementary Fig. S2. (c) Knock-down of CHIP by treatment with siRNA targeting CHIP. The levels of CHIP were examined by western
blotting. Full length images of blots are represented in Supplementary Fig. S2. (d) Effects of CHIP knockdown on YL-109-induced reduction of
anchorage-independent cell growth inMDA-MB-231 cells. CHIP expression was knocked down inMDA-MB-231 cells, and cells were plated in soft agar
dishes in the absence or presence of YL-109 (1 mM). After incubation for 3 weeks, colonies were examined under a microscope and colonies with a
diameter of more than 50 mmwere counted. (e) Effects of CHIP knockdown on YL-109-reduced invasiveness inMDA-MB-231 cells. MDA-MB-231 cells
were knocked down of CHIP and pre-cultured in the absence or presence of YL-109 (1 mM) for 48 h. The cells were seeded onto filters with Matrigel
matrix-coated upper chambers in the absence or presence of YL-109 (1 mM). After 24 h incubation, invaded cells were stained using crystal violet. *
indicates p,0.05, ** indicates p,0.01, and n.s. indicates p.0.05 by student’s T test vs. DMSO-treated cells.
www.nature.com/scientificreports
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Therefore, our results suggest that YL-109 inhibits the properties
of breast cancer stem cells and can be used for patients with drug-
resistant cancer.
In summary, we demonstrated that YL-109 is a novel antitumor
agent that suppresses tumor progression in TNBC cells and inhibits
cancer stem cell properties, unlike other benzothiazoles.
Furthermore, we show that YL-109 induces CHIP expression
through AhR signaling. Taken together, we propose a new thera-
peutic strategy for breast cancer including TNBC, and prodrug of
YL-109 improved water solubility and chemically stability may be
helpful in development of new pharmacological treatments for
TNBC.
Methods
Cell culture.MCF-7, MDA-MB-231 and BT-20 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) or RPMI1640 supplemented with 10% fetal
bovine serum (FBS). For the experiments, cells were seeded in phenol red-freeDMEM
containing 4% charcoal-stripped FBS. After 24 h, the medium was exchanged for
phenol red-free DMEM containing 1% charcoal-stripped FBS with or without
ligands.
RNA interference. For transfection of siRNAs, cells at 30–50% confluency were
transfected with 20 nmol/L of siRNA using Lipofectamine RNAi max (Invitrogen)
according to the manufacture’s protocol. All siRNAs were purchased from
Invitrogen. The siRNA duplexes
CHIP, 59-CCAGCGCUCUUCGAAUCGCGAAGAA-39;
AhR, 59-GAGAAUUCUUAUUACAGGCUCUGAA-39.
α
β
Figure 4 | YL-109 induces CHIP expression through AhR activation. (a) Effects of YL-109 onCyp1a1mRNA expression in breast cancer cells. MCF-7 or
MDA-MB-231 cells were cultured in the absence or presence of YL-109 (1 mM).Cyp1a1mRNA level was quantified using real-time RT-PCRs. (b) Knock-
down of AhR by treatment with siRNA targeting AhR.Western blotting was used to examine the levels of AhR. Full length images of blots are represented
in Supplementary Fig. S2. The representative blots for AhR were cropped to clarify relevant bands. (c) Effects of AhR knockdown on YL-109-increased
CHIP expression. AhR expression was knocked down inMDA-MB-231 cells, and cells were cultured in the absence or presence of YL-109 (1 mM). CHIP
expression was analyzed using real-time RT-PCRs. (d) AhR recruitment to CHIP promoter by YL-109. MDA-MB-231 cells were cultured in the absence
or presence of YL-109 (1 mM). ChIP assay was performed with control IgG or anti-AhR antibodies. Immunoprecipitated DNAwas examined using real-
time RT-PCR and primers specific for the CHIP promoter. Samples were normalized to the amount of input DNA. * indicates p,0.05, ** indicates
p,0.01, and n.s. indicates p.0.05 by student’s T test vs. DMSO-treated cells.
www.nature.com/scientificreports
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StealthTM RNAi reporter control was used as a negative control.
MTT assay. Cells were incubated in DMEM containing 4% charcoal-stripped FBS
with DMSO or YL-109 (1 mM) for 96 h. The proliferation of cultured cells was
measured by MTT assay using the MTT Cell Count Kit (Nakarai tesque).
Poly-HEMA. One gram of poly-(2-hydroxyethyl methacrylate) (poly-HEMA)
(Sigma-Aldrich) was dissolved in 25 mL 99.5% ethanol andmixed overnight at 37uC.
The poly-HEMA stock solution were added to 12-well plates and plates were left to
dry for a fewhours. After drying, the plates werewashedwith PBS. Cells were plated in
the poly-HEMA-coated 12-well plates at a density of 13 105 cells (MCF-7) or 1.53
105 cells (MDA-MB-231) per well and incubated for 24 h. Cells were treated with
0.2% trypan blue. Viable cells were counted using Countess Automated Cell Counter
(Invitrogen).
Soft agar colony-formation assay. For soft agar assays, 23 105 cells were suspended
in DMEM containing 0.35% agar and layered on top of 1 mL of DMEM solidified
with 0.6% agar in each well of a 6-well plate. After growing at 37uC for 3 weeks,
colonies were counted under the microscope. The reported results represent the
averages of three independent experiments.
Invasion and migration assay. The invasive potentials of MDA-MB-231 and BT-20
cells were tested withMatrigel invasion chambers (24-well format, 8 mm pore size; BD
Biosciences). After incubation in DMEM containing 1% charcoal-stripped FBS with
DMSO or YL-109 (1 mM) for 48 h, suspensions (0.5 mL) containing 1 3 105 cells
(MDA-MB-231) or 0.53 105 cells (BT-20) were added with vehicle alone (DMSO) or
YL-109 (1 mM), and transferred into insert chambers. These cells were then incubated
for 24 h at 37uC with 0.75 mL of DMEM containing 4% charcoal-stripped FBS and
each ligand in the bottom chambers. After incubation, the cells on the upper surface of
the filter were removed, and invading cells were fixed in methanol. Fixed cells were
stained with crystal violet and counted under a microscope. Migration assays were
performed using the same procedure, except that the insert chambers were not coated
with Matrigel and cells in chamber were incubated for 12 h.
Tumor xenograft models. BALB/cAjcl-nu/nu female mice at 4-5 weeks of age were
purchased from CLEA Japan. The mice were kept in a pathogen-free environment
under controlled conditions of light and humidity. MCF-7 orMDA-MB-231 cells were
cultured asmonolayers, trypsinized and resuspend inMatrigel (BDBiosciences) at each
13 108 or 13 107 cells/ml. Each mouse was injected subcutaneously with 100 mL of
cell suspension (1 3 107 or 1 3 106 cells) in both flanks. YL-109 was subcutaneously
injected in the scruff of the neck (15 mg/kg) for every 2 days. Tumor growth was
α
Figure 5 | YL-109 suppresses breast cancer progression through AhR signaling. (a and b) Effects of AhR on YL-109-inhibited cell proliferation inMCF-
7 cells.MCF-7 cells were cultured in the absence or presence of YL-109 (1 mM), AhR antagonist a-NF (1 mM) (a).MCF-7 cells knocked down of AhRwere
cultured in the absence or presence of YL-109 (1 mM) (b). The cell viability was measured by MTT assays. (c) Effects of AhR knockdown on YL-109-
inhibited anchorage-independent cell growth in MDA-MB-231 cells. AhR expression was knocked down in MDA-MB-231 cells, and cells were
plated in soft agar dishes in the absence or presence of YL-109 (1 mM). After incubation for 3 weeks, colonies were examined under a microscope and
colonies with a diameter of more than 50 mm were counted. (d) Effects of AhR knockdown on YL-109-reduced invasiveness in MDA-MB-231 cells.
MDA-MB-231 cells were seeded onto filters with Matrigel matrix-coated upper chambers in the absence or presence of YL-109 (1 mM). * indicates
p,0.05, ** indicates p,0.01, and n.s. indicates p.0.05 by student’s T test vs. DMSO-treated cells.
www.nature.com/scientificreports
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monitored twice each week by measuring the tumor size using calipers; tumor volume
was determined using the formula V51/23 larger diameter3 (smaller diameter)2. All
animal experiments were performed in accordance with institutional guidelines.
In vivo lung metastasis analysis. BALB/cAjcl-nu/nu female mice at 4-5 weeks of age
were purchased from CLEA Japan. The tail vein of each mouse was injected with
MDA-MB-231 cells (5 3 105 cells). Forty-two days after injection, the mice were
sacrificed and lung metastases were examined by hematoxylin-eosin (H&E) staining
and immunohistochemistry for human cytokeratin and quantified by real-time RT-
PCRs using primers specific for humanHPRT that did not cross-react with themouse
homologue. Mouse b-actin was used for normalization.
Immunohistochemistry. Immunohistochemistry was performed under contract
with Genostaff Co., Ltd. Tissues were fixed, dehydrated and embedded in paraffin
Figure 6 | YL-109 reduces cancer stem cell properties in MDA-MB-231 cells. (a) Effects of YL-109 on Mammosphere formation. MDA-MB-231 cells
were inoculated onto ultra-low-attachment plates in the absence or presence of YL-109 (1 mM.After 7 days,mammospheres with a diameter ofmore than
100 mmwere counted. The photographs in the left panel show representative mammospheres. The insets in panels showmagnified images. The scale bars
represent 100 mm. The graph in right panel shows the number of mammospheres. (b) Effects of YL-109 on ALDH-positive cell population. MDA-MB-
231 cells were incubated with YL-109 (1 mM) for 96 h andALDH-positive cell populationwasmeasured by the Aldefluor assay kit and flow cytometry. (c)
Effects of YL-109 on the expression of cancer stem cell markers in mammospheres. The mammospheres were collected after 7 days culture on ultra-low-
attachment plates in the absence or presence of YL-109 (1 mM). The gene expressions of Klf-4 and Hes1 were analyzed using real-time RT-PCR. **
indicates p,0.01 by student’s T test vs. DMSO-treated cells.
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were cut at 5 mm thickness. For antigen retrieval, the sections were incubated with
EDTA buffer [10 mMTris-HCl and 1 mM ethylenediaminetetraacetic acid (EDTA)]
(pH 9.0) at 95uC for 20 min, and then treated with 0.3% hydrogen peroxide. After
blocking, the sections were incubated with anti-human-cytokeratin clone MNF-116
(Abcam) (10 mg/ml, overnight at 4uC). Immunostaining was performed with
EnVisionTM system (Dako). Staining of H&E was performed by standard protocol.
Real-time RT-PCR.Tissues and cells were homogenized in 1 mL of Sepazol and total
RNA was extracted according to the manufacturer’s instructions (Nacalai tesque).
cDNA was synthesized from total RNA using RevaTraAce reverse transcriptase
(Toyobo) and oligo dT primer. Real-time PCRs were performed to amplify fragments
representing for the indicated mRNA expression using the Thermal Cycle DiceTM
TP800 (Takara) and SYBR Premix Ex Taq (Takara). The primer sequences can be
found in Supplementary Table S1.
Western blotting. Cells were lysed in TNE buffer [10 mM Tris-HCl (pH 7.8), 1%
Nonidet P-40 (NP-40), 0.15 M NaCl, and 1 mM EDTA], and then immunoblotted
with the appopriate antibodies. A murine hybridoma monoclonal antibody against
humanCHIPwas generated in our laboratory. The antibodies used in this study were:
anti- human CHIP (15500; Green Space Biomed, Japan), AhR (15500; Santa Cruz),
and b-actin (155000; Sigma) antibodies. Specific proteins were visualized using an
enhanced chemiluminescence (ECL) Western blot detection system (Millipore).
Chromatin immunoprecipitation (ChIP) assay. This was done essentially as
described previously34. The DNAwas amplified by real-time PCR as described above.
The primers for real-time PCR are as follows: forward primer: 59-
TCACATGCTTCTCTGCTCTG-39; reverse primer: 59-
GACTGTTGGTAGAGTGGAAG-39 for CHIP gene upstream region. Samples were
normalized based on the amount of input DNA.
Mammosphere formation assay.MDA-MB-231 cells were plated onto 6-well ultra-
low-attachment plates (Corning Costar) at 5 3 103 cells per well. Cells were
maintained in serum-free with a CnT-27 medium and growth additives (CellnTEC
Advanced cell systems)27. After 7 days, over 100 mm spheres were counted.
ALDH assays. The ALDEFLUOR kit (Stem Cell Technologies, Durham, NC, USA)
was used to detect cancer stem cell population with high aldehyde dehydrogenase
(ALDH) enzyme activity, as previously reported35. Briefly, MDA-MB-231 cells were
treated with YL-109 (1 mM) for 4 days. The cells were then incubated in ALDH assay
buffer containing the ALDH substrate (BAAA, 1 mM) for 30 min at 37uC. As a
negative control, cells were stained under identical conditions in the presence of
diethylaminobenzaldehyde (DEAB, 15 mM), a specific ALDH inhibitor. FACSAria II
cell sorter (BD Biosciences) was used to measure the ALDH-positive cell population.
Statistical analysis. Data are representative of at least three different experiments.
Significance of differences was determined by Student t-test analyses or by two-way
ANOVA with Bonferroni’s post hoc test (tumor xenograft experiments).
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